The LH receptor plays an essential role in male and female gonadal function. Together with the FSH and TSH receptors, the LH receptor forms the family of glycoprotein hormone receptors. All glycoprotein hormone receptors share a common modular topography, with an N terminal extracellular ligand binding domain and a C terminal seven transmembrane transduction domain. The ligand binding domain consists of 9 leucine-rich repeats, flanked by N-and C-terminal cysteine rich regions. Recently, crystal structures have been published of the extracellular domains of the FSH and TSH receptors. However, the Cterminal cysteine rich region (CCR), also referred to as the 'hinge region', was not included in these structures. Both structure and function of the CCR therefore remain unknown. In this study we set out to characterize important domains within the CCR of the LH receptor. Firstly, we mutated all cysteines and combinations of cysteines in the CCR to identify the most probable disulphide bridges. Secondly, we exchanged large parts of the LH receptor CCR by its FSH receptor counterparts, and characterized the mutant receptors in transiently transfected HEK293 cells. We zoomed in on important regions by focused exchange and deletion mutagenesis followed by alanine scanning. Mutations in the CCR specifically decreased the potencies of LH and hCG, since the potency of the low molecular weight agonist Org 41841 was unaffected. Using this unbiased approach, we identified Asp 330 and Tyr 331 as key amino acids in LH/hCG mediated signaling.
The glycoprotein hormone luteinizing hormone (LH) has an essential role in reproduction. In both sexes, LH regulates the production of gonadal androgens, which in women are almost completely converted to estrogens. Further, in women the mid-cycle LH peak triggers ovulation of the mature oocyte ready to be fertilized, whereas the closely related pregnancy hormone, chorionic gonadotropin (hCG), supports the corpus luteum of pregancy. Both LH and hCG act by binding and activating the LH receptor. The LH receptor has a modular architecture consisting of an ectodomain or extracellular hormone binding domain (ECD), linked to a seven transmembrane signal transduction domain (7TMD). Together with the receptors for thyroid stimulating hormone (TSH) and follicle stimulating hormone (FSH), the LH receptor belongs to the glycoprotein hormone receptor family. The extracellular ligand binding domain of this family consists of a stretch of nine leucine rich repeats (LRRs), flanked by N terminal and C terminal cysteine rich clusters (NCR and CCR, respectively). The crystal structures that have been determined for major parts of FSHR and TSHR ECDs show that the LRRs are organized as β sheets, and give rise to a curved helical tube of which the concave surface forms the hormone-binding surface (1, 2) . The NCR provides an additional β-strand to the binding surface. Since the CCR was not included in the protein expression procedures to obtain the crystals, its structure remains elusive. LRRs are considered versatile binding motifs often involving protein-protein interactions, and are observed in a large variety of proteins (3, 4) . Also the non-glycoprotein hormone receptor LRRs 2/21 contain an NCR and CCR and in those LRRproteins of which crystal structures have been resolved, the NCR and CCR form β strands that combine seamlessly with the β sheets formed by the LRRs (5, 6) . Thus, the CCR of the glycoprotein hormone receptors may also be expected to form a prolongation of the LRR β sheets. The function of the CCR has been addressed in more detail by receptor mutagenesis studies. Ligand binding studies with mutant rat LH receptors indicate that LRR1-6 contribute most to high-affinity ligand binding, whereas a combined deletion of LRR9 and the CCR did not alter hCG affinity (7) . Truncation of the rat LH receptor demonstrates that neither the 7TMD nor the CCR are essential to high affinity binding (8) . A similar approach in the human LH receptor, systematically truncating the receptor at exon boundaries showed a stepwise decrease in affinity loss with severity of truncation (9) . Here, deleting both 7TMD, and the C-terminal part of the CCR, did not alter hCG affinity. Notably, the above mentioned deletion and truncation mutants failed to be expressed at the plasma membrane. In most LRR proteins the CCR has four cysteines, of which the first two are either directly adjacent or separated by one amino acid resulting in two disulphide bonds (10) . Also in the CCR of the LH receptor the first two (of a total of six) cysteines are located adjacently. Since the CCR is a conserved feature, yet is not required for highaffinity ligand binding, its role may be to structurally preserve the ECD structure, and/or to selectively transduce signals from the ECD to the 7TMD. Crystal structures of the glycoprotein Ibα (GPIbα) suggest a role for the CCR in responding to ligand binding: a 16-residue β-hairpin (β-switch) is formed in the CCR of GPIbα upon binding of the von Willebrand factor (6) . Noteworthy, all disease-causing gain-of-functionmutations are present in this β-switch (11, 12) . Also for the TSH receptor such a concept has been proposed. Based on a series of constitutively active TSH receptors, Mueller and coworkers (13) proposed an activation mechanism in which the CCR is key. The authors propose that the CCR acts as a lever linking the ECD LRRs to the 7TMD, in which the conserved cysteine tandem of the CCR serves as a fulcrum. Modification on either site of the lever, by mutation, ligand interaction, or tryptic clipping, changes the conformation of the CCR, and results in 7TMD activation (13) . Also in the LH receptor, mutation of Ser 277 close to the CCR leads to constitutive receptor activation (14) , supporting a similar mechanism in this receptor as well. Besides via the extracellular domain, the LH receptor can also be activated directly via the 7TMD. Illustrating for this phenomenon is that most of activating LH receptor mutations observed in patients are single amino acid changes within the transmembrane helices (for review: 15,16). Recently, some thienopyr(im)idine derivatives (i.e. Org 41841 and Org 42599) were characterized as a novel class of low molecular weight LH receptor agonists (17, 18) . These ligands can activate the receptor by interacting directly with the 7TMD, rather than with the receptor ectodomain (19, 20) . In the present study we unravel the constellation of disulphide bridges in the CCR, and further set out to characterize the requirements of the CCR for hormone-induced signalling. Hereto we exchanged and deleted (parts of) the LH receptor CCR, followed by detailed alanine scanning. This led to the identification of two amino acid residues Asp 330 and Tyr 331 as key CCR residues, involved in LH/hCG mediated signalling. In addition we introduce the low molecular weight agonists Org 41841 and Org 42599 as tools to evaluate intrinsic receptor functionality.
Experimental procedures

Materials
Unless stated otherwise, cell culture reagents were purchased from Gibco, Invitrogen Corporation (Paysley, UK): restriction enzymes and polymerases from Roche (Almere, The Netherlands); fine chemicals from Sigma Aldrich (Zwijndrecht, The Netherlands); oligonucleotides from Biolegio (Nijmegen, The Netherlands). hCG, LH, Org 41841 and Org 42599 are kind gifts of NV Organon, Oss, The Netherlands.
Construction of WT and mutant LH receptor expression plasmids
Construction of the expression plasmid pSG5-hLHR WT is described elsewhere (21) . An Nterminal HA-tag was inserted immediately Cterminal to the signal peptide by inserting the primer-dimer 3/21 (5'GTACCCATACGATGTTCCAGATTACGC and complement) into the Eco47III site at position 84 in the LH receptor cDNA. In this background, the deletion or domain-exchange LH receptor mutants were created by series of fusion PCRs (see supplementary materials and methods). In short, two or three separate PCR reactions were done to amplify different domains of the the LH receptor or, if required, other receptors (pSG5-FSHR (22) , pSVL-TSHR (23), pCDNA3-GP1bα (6), pOTB7-Nogo66-receptor (5)). By using extended oligos in these PCRs, overlap was created between bordering PCR fragments and in a second series of PCR reactions, this overlap was used to fuse individual fragments and amplify the fusion product. The resulting product was subcloned into the pSG5-5'HA-hLHR WT construct. Alanine scanning mutagenesis was done using QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. Oligonucleotides used for mutagenesis are depicted in supplementary materials and methods. All constructs were verified by dideoxynucleotide sequencing.
Cell culture and transfection HEK 293 cells were maintained in culture medium DMEM/F12 + Glutamax supplemented with 1 x 10 5 IU/l penicillin, 0.1 mg/l streptomycin and 10% FBS. Two days prior to transfection, cells are plated at a density of 20% in 25 cm 2 tissue culture flasks (Nalge Nunc International, Rochester, NY, U.S.A.). For transfection 7 µg LH WT/ mutant receptor cDNA (in pSG5), 1.4 µg pCRE 6 lux, and 1.4 µg pRL-SV40 was added to 350 µl 150 mM NaCl and mixed with 350 µl, 0.03 mg/l PEI (polyetyleneimine, linear MW ~25.000; Polysciences Inc., Warrington, PA, USA) in 150mM NaCl. Medium was replaced by serum free medium and supplemented with cDNA-PEI mixture. After 4 hours, medium was supplemented with FBS to a final concentration of 10%.
Reporter gene analysis
To analyse LH receptor activity, WT and mutant expression constructs were transfected to HEK 293 cells (see above). 24 hours post-transfection, cells were detached using trypsin-EDTA, and transferred to white µClear TC-treated plates (Greiner Bio-one Alphen a/d Rijn, The Netherlands), 48 hours post-transfection, medium was replaced by serum-free culture medium supplemented with 0.1% BSA and 25 mM HEPES and a two-fold dilution series of LH, hCG, Org 41841 or Org 42599. For mass to mole conversion for LH and hCG, molecular weights of 29.5 kDa and 36.7 kDa were assumed, respectively (24, 25) . After six hours stimulation, wells were aspired and cells were lysed with 25 mM Tris-phosphate pH 7.8, 8 mM MgCl, 1 mM dithiothreitol, 15% glycerol, 1% Triton X-100) and analysed for luciferase (cAMP-responsive element driven) and renilla luciferase (transfection control) activities using Dual-Luciferase Reporter Assay System according to manufacturer's instructions (Promega Corporation, Madison, WI, USA). Data were analyzed using Prism3 (Graphpad Software Inc. San Diego, CA, USA). Only ≥ 3-fold changes in EC 50 (compared to WT) are considered relevant, and are tested for statistical significance by Student's t-test. P values <0.05 were considered to indicate a significant difference (*: P < 0.05; **: P < 0.01; ***: P < 0.001).
ELISA
WT and mutant expression constructs were transfected to HEK 293 cells (see above). 24 hours post-transfection, cells were detached using trypsin-EDTA, and transferred to 96 well clear plates (Corning Inc. Corning, NY, USA) that were poly-lysine coated for ELISA. 48h posttransfection, cells were washed with PBS and fixed with freshly made 4% paraformaldehyde in PBS (30 min, 22 °C) and blocked with 3% BSA in PBS (1 h, 37 °C). Wells were washed 4x with PBS and incubated (1 h, 37 °C) with 1:1000 dilution of Anti-HA-Peroxidase, (3F10, Roche, Mannheim, Germany) in PBS, 3% BSA. Wells were washed 6 times 10 minutes with PBS and peroxidase activity was assayed using 1-Step Ultra TMB-ELISA (Pierce, Rockford, IL, USA) according to the manufacturer's instruction.
Results
Constellation of disulphide bridges in the CCR
Despite the apparent structural resemblance of glycoprotein hormone receptors, the overall sequence identity in the ECD is low, approx. 40% (26) . However, several sequence motifs are conserved: 4 cysteines in the N-terminal part of 4/21 the ECD, 9 leucine rich repeat motifs (xxLxLxx), and 6 cysteines at the C-terminal side of the extracellular domain. These cysteines are always present in even numbers, suggesting that they are conserved as disulphide pairs. To study the importance of the 6 cysteines in the CCR we individually mutated them to alanine and assayed the mutant receptors for functionality in a CREdriven reporter gene assay. Mutation of Cys 304 or Cys 336 to alanine does not affect the maximum response to LH ( Figure 1A ), and only results in a small (3 to 5-fold) decrease in LH potency (Supplemental Figure 1) Figure 1A ), and mutant receptors could not be detected at the plasma membrane ( Figure 1B ). Remarkably, CRE signaling remained possible after stimulation of these mutant receptors with Org 42599 ( Figure  1A ). Org 42599 is a low molecular weight LH receptor agonist, based on lead optimization of Org41841 (18) and, as Org41841 binds to and activates the receptor directly at the 7TMD (17, 19, 20) , and does not require the ECD. It should be noted that, compared to WT, not only the maximal effect, but also the potency of Org 42599 was reduced (Supplemental Figure 1) . We observed similar shifts in potencies and maximal effects of both Org 42599 and LH when we transfected decreasing amounts of WT LH receptor plasmid (Supplemental Figure 2) . We utilized the residual Org 42599 responsiveness of individual Cys to Ala mutant LH receptors to probe disulphide bridges in the CCR. We argued that mutation of both cysteines of the same disulphide bridge would have the same effect as mutation of only one cysteine, since in both cases only one bridge is broken. In contrast, mutating two cysteines that are not interconnected would break two disulphide bridges and would aggrevate the effect of the individual mutations. Figure 2 .
LH/hCG mediated signaling requires CCR of glycoprotein hormone receptor
Since sequence homology between the glycoprotein hormone receptors is relatively low, we defined the CCR as the region between LRRs and 7TMD, ranging from the first to the last cysteine (in the LH receptor: Cys 279 to Cys 353 ). To probe the specific relevance of the LH receptor CCR for the function of the LH receptor, we deleted it, or replaced it by CCRs of other related (FSH receptor and TSH receptor) or unrelated proteins (Nogo66 receptor (NgR) and glycoprotein 1bα, (GPIbα)). The latter two are not 7TMD receptors, but do contain LRRs with flanking CCR and NCR of which crystal structures are available (5, 6) . Figure 3 shows that the introduction of non-related CCRs (NgR, GPIbα), as well as the complete deletion of the CCR, rendered the mutant receptors completely unresponsive to LH. Analysis of cell surface expression (by ELISA) showed that these mutant receptors were not expressed at the cell surface (data not shown). In contrast, the CCR of the FSH and TSH receptors are much better tolerated as replacements of the original CCR. These exchange mutants are well-expressed (not shown). Furthermore, the mutant LH receptor in which the complete CCR is replaced by that of the FSH receptor (hereafter referred to F281-352) responds to LH and hCG with unaltered potency (Figure 3 and Table 1 ). Using the TSH receptor as CCR donor, the mutant receptor is also functional, but the potency of LH and the maximal effect are reduced ( Figure 3 and Table 1) . (Table 1) . Using the homologous hormone hCG a similar trend is observed, although effects are generally more moderate ( Table 1) . None of the intercysteine replacement mutants displayed altered receptor expression (Supplemental figure 3) .
Focused deletion within the CCR leads to complete non-responsiveness to LH/hCG
As reported earlier (27) , deletion of the exon 10-encoded part of the LH receptor, (∆290-316), resulted in a mutant receptor for which potencies of especially LH, and to a lesser extent hCG were reduced (15-fold and 4-fold respectively, Table 2 ). Since replacement of the second intercysteine stretch with its FSHR counterpart (F305-335) also effectively reduced the potencies of LH and hCG (28-fold and 13-fold respectively), we expected the overlap with exon 10 to be involved. However, deleting this overlap, i.e. the C terminal twelve amino acids of exon 10 (∆305-316), left the LH and hCG potencies unaffected (Table 2 ). Since the patient phenotype could not be mimicked by deleting amino acids 305-316, we also set out to delete the other amino acids encoded by exon 10 (∆290-303). Remarkably, also this deletion did not result in large changes of LH/hCG potencies (Table 2) . Apparently, the exon 10-encoded part of the second intercysteine stretch, does not mediate the decreased potency observed for FSH receptor exchange mutant F305-335. In sharp contrast, deleting the exon 11-encoded part of this second intercysteine stretch (∆317-335) rendered the LH receptor completely unresponsive to both hCG and LH ( Figure 4A and Table 2 ) without altering its plasma membrane expression ( Figure 4C ). Since the mutation may cause intrinsic incapability of the receptor to signal, we applied the low molecular weight agonist Org 41841. In contrast to the glycoprotein hormones Org41841 binds directly to the transmembrane region and may therefore activate the receptor irrespective of mutations in the CCR. Indeed, despite the complete abolishment of the response to LH and hCG, the ∆317-335 mutant receptor responded with unaltered potency to Org 41841 ( Figure 4B) . Deletion of the N-terminal amino acids of intercysteine domain 2, ∆317-324 did not result in changes in LH/hCG potencies, indicating the importance of amino acids 325-335 in LH/hCG mediated signaling. Figure 5 and Table 3 ). For mutant receptors Trp 329 Ala and Phe 335 Ala, decreases in LH potency were smaller (3-and 4-fold respectively). None of the other mutations resulted in a major change in LH potency. Again, for hCG similar, but milder, changes were observed, while potencies of Org 41841 remained unaltered for all mutant receptors (Table 3) .
Alanine scanning mutagenesis shows that
Discussion
Recently, structures of the extracellular domain of both FSH (2) and TSH receptors (1) have been resolved. Unfortunately, the C terminal cysteine rich region (CCR) was not included in these crystallization attempts and the structure of the CCRs thus remains elusive. To our best knowledge, attempts to provide structural clues on the structure of the CCR have proven unsuccessful. Since disulphide bridges may be 6/21 critical in upholding the structure of the CCR, we set out to unravel the constellation of the six cysteines in this domain. Mutation of individual cysteines to alanines confirmed the finding from Zhang and coworkers (28) (Figure 1 and Supplementary  figure 1) .
Reductions in both potency and maximal effect were also observed after transfecting decreasing amounts of WT LH receptor expression plasmid. This suggests that mutation of any of the 4 cysteines compromises receptor structure to such an extent that expression levels are strongly reduced. 336 Ala as well as the combination of them resulted only in minor changes in LH potency, we can not discriminate between the absence of a third disulphide bridge, or the presence of a third bond that is of little structural importance. The putative third disulphide bridge would result in a cysteine constellation as schematically represented in Figure 2 . Notwithstanding this putative third disulphide bridge, the main disulphide bonding of Cys 279 with Cys 343 and Cys 280 with Cys 353 results in a knot-like structure for the CCR in which amino acid residues 280-343 of the CCR branch off from this cluster of cysteines, facilitating close proximity between the ECD and the 7TMD. The CCR has often been described as a mere capping structure, stabilizing the LRR structure of the ECD although in some cases the CCR has a role in signaling interaction with protein ligands (6) . We decided to address the potential role of the CCR as a 'capping structure' to stabilize the LRR structure, by deleting the complete CCR of the LH receptor. Indeed, this mutant receptor was not expressed at the plasma membrane, indicating the importance for correct folding. We argued that if the sole function of a CCR is 'capping' the LRR, a non-related CCR instead of the native CCR might also be capable to perform this function. We substituted the CCR of the LH receptor with that of the glycoprotein 1bα (Gp1bα) and the Nogo66 receptor (NgR). Both proteins are membrane linked (via a single transmembrane domain or a GPI anchor, respectively) and their crystal structures have been resolved (5, 6) , revealing the classical LRR architecture, in which both NCR and CCR are a continuation of the LRR β-strands. If replacement with these unrelated CCRs would generate a functional LH receptor, homology modeling of the LH receptor CCR with these proteins would be feasible. Unfortunately, replacement with any of these structures did not result in rescue of the LH/hCG functionality. In contrast, replacement of the CCR with its homologous structure derived from the related FSH or TSH receptors was able to reinstate LH/hCG responsiveness indicating that the overall fold of the CCR is conserved among the glycoprotein hormone receptors. Indeed, replacement of the complete LH receptor CCR by the CCR of the FSH receptor was accepted without a change in receptor phenotype. Interestingly, partial replacement resulted in a full spectrum of effects: LH potencies were left unchanged (F281-303; F337-342), decreased (F305-352; F305-335); or even (marginally) increased (F281-342, F344-352) . Apparently, there is cooperativity within the CCR that is dependent on the presence of interacting motifs that probably have co-evolved. Since F305-352 and especially F305-335 resulted in strong decreases in LH potencies, we assumed the region 305-335 harbors important LH receptor residues. Part of this 305-335 region is encoded by exon 10. Gromoll and coworkers have described a patient in which exon 10 of the LH receptor was genomically deleted (29) , resulting in a 28 amino acid deletion within the CCR of the LH receptor (∆290-317). This patient was virilized, as a result of responsiveness to placental hCG, but was blocked in pubertal development, since his LH receptor did not respond to LH. In vitro characterization of the ∆290-317 mutant receptor verified that the patient's symptoms were represented at the receptor level: a strongly decreased LH potency, and more marginally 7/21 affected hCG potency (Table 2 and ref 27) . However, deletion of the amino acids common to exon 10 and 305-335, nor the other part of exon 10 had a strong effect on LH or hCG potencies. Apparently, not the specific amino acids encoded by exon 10, but other characteristics, such as the overall length, of this fragment are important. Possibly, the exon 10-encoded part of the receptor is required to create the topology in which critical residues in the CCR can optimally interact with other elements of the receptor or with the hormones LH and hCG themselves. In contrast to exon 10, deletion of the exon 11-encoded amino acids of 305-335, ∆317-335, did decrease LH/hCG potency, even to a level at which no LH/hCG-mediated activation could be detected. By means of alanine scanning Asp 330 and Tyr 331 were identified as key residues within the CCR. Interestingly, using a different approach, Costagliaola and colleagues identified Tyr 385 of the TSHR, analogous to the LH receptor Tyr 331 as a key residue (30) . These authors demonstrated that Tyr 385 of the TSHR was sulfated and that the introduction of this negative charge was essential for TSH signal transduction (30) . Sulfation is also suggested for the analogous Tyr residues in the LH and FSH receptor (30, 31) , the mechanistic role of sulfation in signal transduction remains unknown. Throughout this study, we observed that changes in potency of LH coincided with changes in potency of hCG, although the latter were always milder. The hormones share a common α-subunit, and also LHβ and hCGβ are highly similar. hCGβ is mainly distinguished by the presence of a highly glycosylated 30 amino acid extension called Cterminal peptide (CTP, ref 32) . This CTP therefore likely mediates the difference in CCR mutation sensitivity. In the absence of a crystal structure of the LH receptor encompassing both CCR and hCG, the mode of interaction between CCR and CTP remains speculative. It is however clear, that when studying the effects of mutations of the LH receptor, LH should be included as a ligand of choice, and not just the easier available hCG. Our data suggest that the CCR plays a pivotal role in LH/hCG mediated signaling. Since high-affinity LH/hCG binding is thought to reside within the LRRs of the ECD, the CCR must act at a later stage of receptor activation. Generally two phenomena could account for this later stage in activation: either the CCR interacts with LH/hCG via low affinity interaction and 'guides' the hormone to interact with the 7TMD, as recently suggested by Rapoport and coworkers (33), or the CCR itself acts as the true agonist. The latter option implies that the LRR changes conformation upon LH/hCG binding; this conformational change in turn causes the CCR, and likely Asp 330 and Tyr 331 , to establish contacts with the 7TMD and that this finally leads to activation. Such a phenomenon is well accepted in protease-activated G protein coupled receptors. In these receptors a cryptic ligand, present in the receptor, is unmasked upon protease cleavage of the receptor (34). Also for class B GPCRs, an 'agonist within' has been proposed that is unmasked upon ligand binding to the extracellular domain (35).The CCR of the TSH receptor is proposed to act as an inverse agonist until ligand binding, upon which it switches to an agonist (26, 36 (17) . The prototype of this class is Org 41841, and acts as a submicromolar potency agonist of the LH receptor (Table 2 and ref 17) . Based on this prototype, also the more potent Org 42599 was developed (18) . In contrast to the glycoprotein hormones hCG and LH, Org 41841 does not bind to the ECD of the receptor, but directly to the 7TMD (17, 19, 20) . In this study we exploited this feature to study the functional intactness of the mutant LH receptor proteins, i.e. do the expressed proteins survive the folding quality control system and are they able to signal to the intracellular transduction systems? Thus, the ∆317-335 mutant LH receptor is expressed at the plasma membrane (as determined by cell surface ELISA), yet does not respond to LH and hCG. Org 41841 provided a valuable tool to demonstrate that the absence of effect of LH or hCG did not result from receptor misfolding, since Org 41841 activates this mutant LH receptor with the same potency and effect as the WT receptor. Therefore it can be concluded that the ∆317-335 mutant LH receptor is intrinsically capable of signaling, and thus correctly folded. In summary, we unravelled the requirements of the Supplemental figure 3 
